AstraZeneca and Redx Pharma are teaming up in a research collaboration aimed at searching for and developing new molecules targeting a genetic driver of tumor growth and survival. Per the agreement, Redx Pharma will use its early-stage drug discovery capabilities to identify novel leads, whereupon AZ will support further development of those leads via its Oncology Innovative Medicines group. AZ says the research will complement its strategic approach focused on genetic drivers of cancer and mechanisms of resistance to cancer therapies.
AZ is giving Redx Pharma an upfront payment for an undisclosed amount, plus Redx Pharma could be eligible for development and commercial milestones in addition to tiered royalties as the program progresses. AZ says it will have the sole rights to further develop and commercialize any program resulting from the collaboration to add to its portfolio of cancer medicines.
Redx Pharma, the company says, was one of the first tenants at the BioHub at Alderley Park in Cheshire, which AZ set up in 2013. Scientists from AZ and Redx will be working together at Alderley Park as well as at Redx’ Liverpool facility where the firm says the project will be based.
"This collaboration demonstrates the value of the BioHub and the open, collaborative environment that has been created at Alderley Park," Susan Galbraith, head of the Oncology Innovative Medicines Unit at AZ, commented. "It also illustrates AstraZeneca's continued commitment to supporting science in the U.K., building on our many existing collaborations with organizations across academia and industry."